Moderna R&D day: $1 billion in cost cuts, 10 product launches
WEBSep 12, 2024 · From 2026 to 2028, Moderna expects a compounded annual growth rate of more than 25% as new products launch. Bancel said the company’s rate of success for developing drugs from phase one to phase...
News Details - Moderna
WEBMar 26, 2024 · The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines.
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
WEBAugust 22, 2024. Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent...
News Details - Moderna
WEBMar 27, 2024 · Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development. Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024.
News Details - Moderna
WEBSep 11, 2023 · Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines …
Cambridge-based Moderna lays out plan to slice research and …
WEBSep 13, 2024 · Moderna said it planned an approximately 20% reduction in expected research and development expenses for 2025 to 2028 from $20 billion to $16 billion. It expects a reduction of about $1.1 billion ...
Moderna says its RSV shot is 50% effective across a second season
WEBNEW YORK, June 26 (Reuters) - Moderna Inc (MRNA.O) respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.
News Details - Moderna
WEBOct 4, 2023 · mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines. Company to begin Phase 3 trial of mRNA-1083 in adults 50 years and above.
News Details - Moderna
WEBJan 8, 2024 · Moderna will enter the RSV market with a strong competitive profile as the only pre-filled syringe product available at the time of launch, along with robust efficacy data, a well-established safety and tolerability profile, and widespread consumer awareness and demand established in 2023.
Moderna, Inc. (MRNA) Latest Stock News & Headlines - Yahoo …
WEBGet the latest Moderna, Inc. (MRNA) stock news and headlines to help you in your trading and investing decisions.
Skip to content